Acrivon Therapeutics

Manufacturing · Massachusetts, United States · 51-200 Employees

View Company Info for Free

Overview

Headquarters

480 Arsenal Way Ste 100, Watertown, Mass...

Phone Number

(617) 207-8979

Revenue

$70.4 Million

Stock Symbol

ACRV

Industry

Manufacturing Pharmaceuticals Business Services Research & Development

About Acrivon Therapeutics

Acrivon is focused on developing best-in-class targeted therapies to enhance the lives of cancer patients through its proprietary AP3 precision medicine platform. The company aims to revolutionize precision oncology by accurately matching drug candidates with patients whose tumors are predicted to be sensitive, thereby improving therapeutic outcomes. Acrivon's pipeline includes advanced programs targeting DNA Damage Response and other critical cancer pathways, with its lead candidate ACR-368 currently in phase 2 clinical development. The company seeks strategic partnerships for co-development and is committed to addressing the world's most pressing cancer challenges.Explore more
Acrivon Therapeutics's Social MediaSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: ACRVShow more

Acrivon Therapeutics Org Chart

PhoneEmail
MM
United States flag for contact location.

Chief Legal Officer

PhoneEmail
RH
United States flag for contact location.

Chief Financial Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
PM
United States flag for contact location.

Global Regulatory Affairs Head

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Compare Similar Companies to Acrivon Therapeutics

Compare insights from companies similar to Acrivon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Acrivon Therapeutics

$70.4M
51-200
Public
$100M
2018
MM
Mary-Alice MillerChief Legal Officer
$104.2M
51-200
Public
$528.8M
2018
$49.6M
51-200
Public
$599M
2010
John Hayslip, Chief Medical Officer at VERASTEM ONCOLOGY
John HayslipChief Medical Officer
$15M
51-200
Private
$181.5M
2015
$13.9M
11-50
Private
-
-
N/A
$13.1M
51-200
Private
$128M
2015
Scott Tomlins, Chief Medical Officer at Strata Oncology
Scott TomlinsChief Medical Officer
Illustration of an envelope

Acrivon Therapeutics Tech Stack

A closer look at the technologies used by Acrivon Therapeutics

Top Manufacturing Companies

Frequently Asked Questions Regarding Acrivon Therapeutics

What is Acrivon Therapeutics's stock symbol?
Acrivon Therapeutics's stock symbol is ACRV
What is Acrivon Therapeutics's official website?
Acrivon Therapeutics's official website is www.acrivon.com
What is Acrivon Therapeutics's Revenue?
Acrivon Therapeutics's revenue is $70.4 Million
What is Acrivon Therapeutics's SIC code?
Acrivon Therapeutics's SIC: 28,283
What is Acrivon Therapeutics's NAICS code?
Acrivon Therapeutics's NAICS: 32,325
How many employees does Acrivon Therapeutics have?
Acrivon Therapeutics has 51-200 employees
What industry does Acrivon Therapeutics belong to?
Acrivon Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, Business Services
What is Acrivon Therapeutics competition?
Acrivon Therapeutics top competitors include: Strata Oncology, TYRA, KSQ Therapeutics, VERASTEM ONCOLOGY
What technology does Acrivon Therapeutics use?
Some of the popular technologies that Acrivon Therapeutics uses are: WordPress.org, PHP, R, Microsoft 365
Who is the CFO of Acrivon Therapeutics?
Acrivon Therapeutics's CFO is Rasmus Holm-Jorgensen
How do I contact Acrivon Therapeutics?
Acrivon Therapeutics contact info: Phone number: (617) 207-8979 Website: www.acrivon.com
What does Acrivon Therapeutics do?

Acrivon is focused on developing best-in-class targeted therapies to enhance the lives of cancer patients through its proprietary AP3 precision medicine platform. The company aims to revolutionize precision oncology by accurately matching drug candidates with patients whose tumors are predicted to be sensitive, thereby improving therapeutic outcome... s. Acrivon's pipeline includes advanced programs targeting DNA Damage Response and other critical cancer pathways, with its lead candidate ACR-368 currently in phase 2 clinical development. The company seeks strategic partnerships for co-development and is committed to addressing the world's most pressing cancer challenges.Read More

What are Acrivon Therapeutics social media links?
Acrivon Therapeutics Linkedin page
Who invested in Acrivon Therapeutics?
Acrivon Therapeutics has 4 investors including Surveyor Capital, Wellington Management, RA Capital Management and Perceptive Advisors.
Is Acrivon Therapeutics a public company?
Yes, Acrivon Therapeutics is a public company and is traded under the symbol ACRV
See more information about Acrivon Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.